Skip to main content
. Author manuscript; available in PMC: 2008 May 21.
Published in final edited form as: Antiviral Res. 2006 Jun 14;73(1):12–23. doi: 10.1016/j.antiviral.2006.05.017

Fig. 5.

Fig. 5

Western-blot analysis to evaluate inhibition of expression of KSHV lytic genes downstream from RP1, in RP1-treated BCBL-1 cells. Expression of vIL-6, vIRF-1, and a glycoprotein encoded by ORF-K8.1A in TPA-induced BCBL-1 cells was reduced with increasing RP1 P-PMO concentration (A). CP1 P-PMO did not cause a detectable change (B). Quantitative image analysis confirms the dose-responsive inhibition of vIL-6 (C) and vIRF-1 (D) in the cells treated with RP1 P-PMO in comparison to mock-treated cells.